Fighting cancer / Columns / The Foreigner

Fighting cancer. A Norwegian serial entrepreneur continues to support the development of innovative cancer treatments through his latest startup. Roy Hartvig Larsen’sOncoinvent is developing therapeutics to combat various cancers, and they are now conducting preclinical documentation studies. The main mechanism of their products is the delivery of tumor-cell killing doses of radiation. Radioisotopes are combined with carriers for optimal delivery of injected doses for treatment of cancers. In 1997, Mr Larsen was the main founder of the biotech company Algeta and served as managing director and later chief scientific officer from 1997-2006 and was also a board member from 1997-2003. The company marketed the first alpha particle emitting radiopharmaceutical for cancer treatment.

cancer, treatment, research, health, startup, entrepreneur, paywall



The Foreigner Logo

The Foreigner is an online publication for English speakers living or who have an interest in Norway. Whether it’s a glimpse of news or entertainment you’re after, there’s no need to leave your linguistic armchair. You don’t need to cry over the demise of the English pages of Aftenposten.no, The Foreigner is here!

Norske nyheter på engelsk fra Norge. The Foreigner er en engelskspråklig internett avis for de som bor eller som er interessert i Norge.

Google+ Google+ Twitter Facebook RSS RSS



Columns Article

LATEST:

Fighting cancer

Published on Friday, 4th November, 2016 at 09:15 under the columns category, by Rasmus Falck.

A Norwegian serial entrepreneur continues to support the development of innovative cancer treatments through his latest startup.

Genetic testing
Genetic testing
Photo: US Dept. of Health/Human Svcs./Wikimedia


Roy Hartvig Larsen’sOncoinvent is developing therapeutics to combat various cancers, and they are now conducting preclinical documentation studies. The main mechanism of their products is the delivery of tumor-cell killing doses of radiation. Radioisotopes are combined with carriers for optimal delivery of injected doses for treatment of cancers.

In 1997, Mr Larsen was the main founder of the biotech company Algeta and served as managing director and later chief scientific officer from 1997-2006 and was also a board member from 1997-2003. The company marketed the first alpha particle emitting radiopharmaceutical for cancer treatment.

The company went public on the Oslo Stock Exchange some 10 years later. The product received U.S. Food and Drug Administration approval in 2013 to treat castration-resistant prostate cancer, symptomatic bone metastases, and unknown visceral metastatic disease.

Algeta and Bayer AG had anchored a development and commercialization deal for the product (Xofigio) in September 2009 with a total deal size of USD 800 million, and in December 2013, Bayer offered a full acquisition of Algeta for USD 2.9 billion. The deal was completed in March 2014.

Hartvig Larsen went on to become one of the founders of Nordic Nanovector in 2009. The company leveraged expertise in targeted cancer therapy from the Norwegian Radium Hospital. In 2010 the first patent application was filed for their main product. The next year the first fulltime employees were hired.

In 2013 the venture fund Health Cap invested NOK 50 million. Last year the company raised NOK 575 million in gross proceeds when listed on the Oslo Stock Exchange; no other European biotech company has raised so much equity capital when introduced on the stock exchange. In 2014 the main products patent was approved in the U.S. Hartvig Larsen was the chairman on the board from 2009 to 2014 and a member of the board until 2016.

At the presentation of the company’s results for the second quarter this year, the CEO commented that the first half had been very positive for the company and that it continues the positive momentum of 2015.

Hartvig Larsen’s latest startup, Oncoinvent, successfully completed a private placement last spring. The share offering was directed towards the company’s existing shareholders and a limited number of private investors. The issue was oversubscribed and provided NOK 15 million. The company was priced at NOK 77 million and 48 investors participated.

The proceeds of this will be used to build manufacturing capacity for the clinical development program of the company’s lead compound, a new alpha-therapeutic designed for local treatment of micrometastases. The company will further use the funds to expand its activities and acquire the additional human resources required for preparations of its first clinical trial.

Rasmus Falck is a strong innovation and entrepreneurship advocate. The author of “What do the best do better” and “The board of directors as a resource in SME,” he received his Master’s degree from the University of Wisconsin-Madison. He currently lives in Oslo, Norway.

This article originally appeared in the Nov 4, 2016 issue of the Norwegian American Weekly. Click here to subscribe.



Published on Friday, 4th November, 2016 at 09:15 under the columns category, by Rasmus Falck.

This post has the following tags: cancer, treatment, research, health, startup, entrepreneur, paywall.





  
Do NOT follow this link or you will be banned from the site!